MAGE-A4 TCR Gene-Modified T Cells

MAGE-A4 TCR Gene-Modified T Cells is an autologous T-cell receptor engineered T-cell (TCR-T) therapy developed by Tianjin Medical University Cancer Institute and Hospital for the treatment of advanced malignant solid tumors. The therapy consists of patient-derived T cells genetically engineered to express a codon-optimized T-cell receptor (TCR) specific for the melanoma-associated antigen A4 (MAGE-A4), a cancer-testis antigen, presented in the context of HLA-A*2402. A key feature of this specific construct is the incorporation of small interfering RNA (siRNA) to downregulate the expression of the endogenous TCR, thereby reducing TCR mispairing and enhancing the surface expression and potency of the MAGE-A4-specific TCR. In clinical protocols, the therapy is administered intravenously following lymphodepleting chemotherapy and is typically supplemented with interleukin-2 (IL-2) and MAGE-A4 peptide vaccinations to support the expansion and persistence of the modified T cells. It is currently being investigated in Phase 1 trials for various MAGE-A4-positive malignancies, including non-small cell lung carcinoma, malignant melanoma, and esophageal carcinoma.

Other names

MAGE-A4 TCR-T cellsMAGE-A-4 TCR-T cellsMAGE-A 4 TCR-T cellsMAGE-A4 TCR Gene-Modified T lymphocytesMAGE-A-4 TCR Gene-Modified T lymphocytesMAGE-A 4 TCR Gene-Modified T lymphocytesMAGE-A4 TCR Gene-Modified T Cells-Tianjin Medical University Cancer Institute and Hospital-malignant solid tumor-non-small cell lung carcinoma-malignant melanomaMAGE-A-4 TCR Gene-Modified T Cells-Tianjin Medical University Cancer Institute and Hospital-malignant solid tumor-non-small cell lung carcinoma-malignant melanomaMAGE-A 4 TCR Gene-Modified T Cells-Tianjin Medical University Cancer Institute and Hospital-malignant solid tumor-non-small cell lung carcinoma-malignant melanoma